NLS Allenex

CareDx’s offer to the shareholders of Swedish Allenex has been accepted by shareholders holding an aggregate of 118,207,862 shares, corresponding to approximately 98.3% of the total number of shares in Allenex. CareDx declares the offer unconditional and completes the offer.  The settlement is expected to occur on or around April 13, 2016. On December 16, […]

CareDx announced an agreement to acquire approximately 78% of the outstanding shares of Allenex AB from its three principal shareholders, and plans to launch a tender offer for the remaining 22% of the shares of Allenex in the first quarter of 2016. The Allenex Board of Directors has unanimously recommended that Allenex shareholders accept the […]

During 2014, Allenex started to develop a brand new HLA typing tests based on the method of real-time PCR. The aim is to launch the products during the second quarter of 2015. “HLA typing based on the method of real-time PCR is more rapid and efficient. It is especially valuable for on-call deceased donor typing for […]

Through its subsidiary Olerup Allenex has decided to extend the agreement with the Australian company Conexio Genomics. Allenex announced a five year exclusive and global marketing and sales agreement with Conexio back in 2011 for SBT Resolver for HLA typing using the SBT technology. Software for sequence analysis had also been included in the agreement. Conexio and Allenex now […]

Investment company Allenex has agreed to sell its holding in Anamar AB to the company’s main owner Koncentra Holding. Allenex became an owner in AnaMar 1998, whose focus area is chronic joint diseases. However, Allenex has not participated in the financing of AnaMar in recent years and the equity that now is being sold equal about 2,1 […]